CBI’s longstanding Gross-to-Net Summit is built for the learning needs and changing dynamics of pharmaceutical, biotech and generic drug companies. Attendees gain best practices for a well-designed, multi-faceted approach to GTN management for enhanced visibility, profitability and control.

This in-depth event showcases industry models for GTN estimates, analytics and reporting, offers multiple workshops and features three tracks of relevant and timely content. Attendees choose from Branded Pharma, Generic Products and Emerging Biotech, with streams of sessions tailored to your business needs.

Cumberland Principal Michael Flinn will moderate a panel titled “New Launch Planning – Models and Approaches for Estimating GTN Accruals” during the conference.